Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Company

Hetero Labs Limited

Pharmaceutical intelligence for Hetero Labs Limited with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
3
Catalysts
2
Assets
3

Recent signals(3)

RegulatoryJuly 22, 2026

FDA Submission Update for ANDA220866 by Hetero Labs Limited

Hetero Labs Limited has submitted ANDA220866 with a standard review priority.

StrategyJuly 12, 2026

Hetero Labs submits ANDA220421 for Vemagal with standard review priority

Hetero Labs Limited has submitted ANDA220421 for Vemagal, currently under standard review.

RegulatoryJuly 11, 2026

FDA Submission for Cyclophosphamide by Hetero Labs Limited

Hetero Labs Limited has submitted an original application for Cyclophosphamide under ANDA219271 with standard review priority.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity(2)

RegulatoryJuly 22, 2026

FDA Submission Update for ANDA220866 by Hetero Labs Limited

Hetero Labs Limited has submitted ANDA220866 with a standard review priority.

RegulatoryJuly 11, 2026

FDA Submission for Cyclophosphamide by Hetero Labs Limited

Hetero Labs Limited has submitted an original application for Cyclophosphamide under ANDA219271 with standard review priority.

Clinical activity

No signals indexed for this entity yet.

Competitive activity

No signals indexed for this entity yet.

Assets

Cyclophosphamide →
FDA →
Vemagal →

Therapeutic areas

Chemotherapy →
Generic Drug →
Neurology →
Neurology · Generic Drug →
Not specified →
Oncology →
Oncology · Chemotherapy →

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.